Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
112M
-
Number of holders
-
57
-
Total 13F shares, excl. options
-
36.6M
-
Shares change
-
+2.12M
-
Total reported value, excl. options
-
$176M
-
Value change
-
+$9.04M
-
Put/Call ratio
-
2.78
-
Number of buys
-
27
-
Number of sells
-
-31
-
Price
-
$4.82
Significant Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q3 2022
73 filings reported holding ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share as of Q3 2022.
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) has 57 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.6M shares
of 112M outstanding shares and own 32.7% of the company stock.
Largest 10 shareholders include FMR LLC (7.67M shares), Redmile Group, LLC (7.51M shares), JPMORGAN CHASE & CO (3.42M shares), ALLIANCEBERNSTEIN L.P. (2.92M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.39M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.88M shares), PICTET ASSET MANAGEMENT SA (1.3M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.19M shares), Vantage Consulting Group Inc (1.19M shares), and GCM Grosvenor Holdings, LLC (735K shares).
This table shows the top 57 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.